Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

References

• WHO C. Key facts. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer [last accessed 5 May 2021].
   Google Scholar
• El-Zahabi M. Design, molecular modeling and synthesis of new immunomodulatory agents for biological studies. Al-Azhar J Pharm Sci 2021;64:1–20.
   Google Scholar
• Dawoud N, El-fakharany E, El-Gendi H, et al. Consolidated antimicrobial and anticancer activities through newly synthesized novel series of pyrazoles bearing indazolylthiazole moiety: characterization and molecular docking. Egypt J Chem 2021;64:5–6.
   Web of Science ®Google Scholar
• Manning G, Whyte D, Martinez R, et al. cAMP-dependent protein kinase from Plasmodium falciparum: an update. Trends Biochem Sci 2002;27:514–20.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19:117–23.
   PubMed Web of Science ®Google Scholar
• Modi SJ, Kulkarni VM. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. Med Drug Discov 2019;2:100009.
   Google Scholar
• Wang C, Gao H, Dong J, et al. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation. Bioorg Med Chem 2014;22:277–84.
   PubMedGoogle Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 2016;17:611–25.
   PubMed Web of Science ®Google Scholar
• Adel M, Serya RA, Lasheen DS, Abouzid KA. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, biological evaluation and molecular modeling. Bioorg Chem 2018;81:612–29.
   PubMed Web of Science ®Google Scholar
• Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007;13:5544s–8s.
   PubMed Web of Science ®Google Scholar
• Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014;2(12):123
   PubMedGoogle Scholar
• Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219–27.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2:1097–105.
   PubMedGoogle Scholar
• Roskoski R. Jr. Vascular endothelial growth factor (VEGF) signaling in tumour progression. Crit Rev Oncol Hematol 2007;62:179–213.
   PubMed Web of Science ®Google Scholar
• Poon RT-P, Fan S-T, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207–25.
   PubMed Web of Science ®Google Scholar
• Tugues S, Koch S, Gualandi L, et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88–111.
   PubMed Web of Science ®Google Scholar
• Shi L, Wu T-T, Wang Z, et al. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Eur J Med Chem 2014;84:698–707.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–44.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen M, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106:1722–7.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505–12.
   PubMed Web of Science ®Google Scholar
• Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632–40.
   PubMed Web of Science ®Google Scholar
• Kong LJ, Li H, Du YJ, et al. Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice. Mol Med Rep 2017;15:2604–10.
   PubMed Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, Angiolini M. Through the “gatekeeper door”: exploiting the active kinase conformation. J Med Chem 2010;53:2681–94.
   PubMed Web of Science ®Google Scholar
• Lintnerová L, García-Caballero M, Gregáň F, et al. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex-medicinal chemistry consequences of a TKs analysis. Eur J Med Chem 2014;72:146–59.
   PubMed Web of Science ®Google Scholar
• Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. Anti-Cancer Agents Med Chem 2013;13:731–47.
   Google Scholar
• Regan J, Pargellis CA, Cirillo PF, et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorg Med Chem Lett 2003;13:3101–4.
   PubMed Web of Science ®Google Scholar
• Lee K, Jeong K-W, Lee Y, et al. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 2010;45:5420–7.
   PubMed Web of Science ®Google Scholar
• Xie Q-Q, Xie H-Z, Ren J-X, et al. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J Mol Graph Model 2009;27:751–8.
   PubMed Web of Science ®Google Scholar
• Aziz MA, Serya RA, Lasheen DS, et al. Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents. Sci Rep 2016;6:1–20.
   PubMed Web of Science ®Google Scholar
• Abdallah AE, Eissa SI, Al Ward MMS, et al. 2021) Design, synthesis and molecular modeling of new quinazolin-4 (3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Bioorg Chem 2021;109:104695.
   PubMed Web of Science ®Google Scholar
• Machado VA, Peixoto D, Costa R, et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497–509.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Hulme C, Hurley LH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem 2010;18:5738–48.
   PubMed Web of Science ®Google Scholar
• Plé PA, Jung F, Ashton S, et al. Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett 2012;22:262–6.
   PubMed Web of Science ®Google Scholar
• Abd-Elhamid AI, El-Gendi H, Abdallah AE, et al.. Novel Nanocombinations of l-tryptophan and l-cysteine: preparation, characterization, and their applications for antimicrobial and anticancer activities. Pharmaceutics 2021;13:1595.
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000;113:753–7.
   PubMed Web of Science ®Google Scholar
• Lo KK-W, Lee TK-M, Lau JS-Y, et al. Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. Inorg Chem 2008;47:200–8.
   PubMed Web of Science ®Google Scholar
• bank, P. d., R.P.D. Bank, 2021. Available from: https://www.rcsb.org/structure/4ASD [last accessed 1 Mar 2021].
   Google Scholar
• Ibrahim MK, Eissa IH, Alesawy MS, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists. Bioorg Med Chem 2017;25:4723–44.
   PubMed Web of Science ®Google Scholar
• Alesawy MS, Abdallah AE, Taghour MS, et al. Silico studies of some isoflavonoids as potential candidates against COVID-19 targeting human ACE2 (hACE2) and viral main protease (Mpro). Molecules 2021;26:2806.
   PubMed Web of Science ®Google Scholar
• PerkinElmer. ChemBioDraw Ultra 14.0 PerkinElmer; 2012. Available from: https://shopinformatics.perkinelmer.com/search. [last accessed 31 December 2021].
   Google Scholar
• Alesawy MS, Al‐Karmalawy AA, Elkaeed EB, et al. Design and discovery of new 1, 2, 4‐triazolo [4, 3‐c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie 2021;354:2000237.
   PubMed Web of Science ®Google Scholar
• El-Adl K, Ibrahim M-K, Alesawy MS, Eissa IH. [1, 2, 4] Triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4′, 3′-c] quinazoline derived DNA intercalators: design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorg Med Chem 2021;30:115958.
   PubMed Web of Science ®Google Scholar
• Abdallah AE, Alesawy MS, Eissa SI, et al. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. N J Chem 2021;45:16557–71.
   Web of Science ®Google Scholar
• Avdeenko A, Konovalova S, Sergeeva A, et al. Synthesis and structure of N-alkyl (aryl) aminocarbonyl-1, 4-benzoquinone imines. Russian J Org Chem 2008;44:1765–72.
   Web of Science ®Google Scholar
• El-Gamal MI, Zaraei S-O, Foster PA, et al. A new series of aryl sulfamate derivatives: design, synthesis, and biological evaluation. Bioorg Med Chem 2020;28:115406.
   PubMed Web of Science ®Google Scholar
• Kuksenok VY, Shtrykova VV, Filimonov VD, Sidel’nikova S. Efficient one-stage procedure of Beckmann ketones rearrangement in the presence of hydroxylamine. Russian J Org Chem 2016;52:196–9.
   Web of Science ®Google Scholar
• Gao X-h, Liu L-b, Liu H-r, et al. Structure–activity relationship investigation of benzamide and picolinamide derivatives containing dimethylamine side chain as acetylcholinesterase inhibitors. J Enzyme Inhibit Med Chem 2018;33:110–4.
   PubMed Web of Science ®Google Scholar
• Shah D, Lakum H, Chikhalia K. Synthesis and in vitro antimicrobial evaluation of piperazine substituted quinazoline-based thiourea/thiazolidinone/chalcone hybrids. Russian J Bioorg Chem 2015;41:209–22.
   Web of Science ®Google Scholar
• Lee S-H, Kim N, Kim S-J, et al. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 2013;139:1279–94.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358–64.
   PubMed Web of Science ®Google Scholar